Nobel pharmacodynamics evaluation of molecular targeting agents: PHarmacokinetic/PHarmacodynamic Assessment on Malignant Effusions (PHAME)

2014 Fiscal Year Final Research Report

• Project/Area Number: 23501314
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Clinical oncology
• Research Institution: Aichi Medical University
• Principal Investigator: KUBO Akihito 愛知医科大学, 医学部, 教授 (60416245)
• Co-Investigator(Renkei-kenkyūsha): KOU Yasuhiro 和歌山県立医科大学, 医学部, 講師 (80426519) ; FUKUOKA Junya 長崎大学, 医学部, 教授 (00324575) ; TAKADA Minoru 阪和第二泉北病院, 副院長 (20373516) ; KAWAGUCHI Tomoya 大阪市立大学, 医学部, 教授 (70254422) ; ISA Shun-Ichi 独立行政法人国立病院機構, 近畿中央胸部疾患センター臨床研究センター, 研究員 (60421913)
• Project Period (FY): 2011-04-28 – 2015-03-31
• Keywords: 非小細胞肺癌 / 癌性胸膜炎 / 分子標的治療 / 薬力学 / 薬物動態 / FDG-PET / 化学療法 / サイトケラチン

Outline of Final Research Achievements

Objective: Pharmacokinetics (PK) / pharmacodynamics (PD) of molecular targeting agents (MTAs) in non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE) are evaluated.
Methods: MPE and blood samples are serially collected from patients with NSCLC and MPE undergoing molecular targeting therapy (MTT) and chest tube drainage, and analyzed for targeted signaling pathways. PD is also evaluated by bio-imaging using 18F-FDG-PET in NSCLC patients undergoing MTT and those undergoing cytotoxic chemotherapy (CC).
Results: MPE is a suitable condition for intensive PK/PD assessments of MTAs with less hematologic toxicities. PD evaluation using PET more clearly predicts clinical outcomes in patients undergoing MTT compared with those undergoing CC.

Free Research Field

臨床腫瘍学、臨床試験、分子生物学、呼吸器内科学